Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

Nightingale Health

1.18 EUR0.00 %26.10. klo 12.00
4,813 following

HEALTH

NASDAQ Helsinki

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Short Selling
Investor views
Compare
0.00 %
+20.65 %
+43.20 %
-3.28 %
-42.44 %
-48.02 %
+14.56 %
-65.21 %
-77.09 %

Nightingale Health operates in the medical technology sector. The company specializes in the development of medical technology products. The product portfolio is broad and includes platforms and services within blood analysis that are used for disease prevention purposes. In addition to the main business, service and related ancillary services are also offered. The business is operated globally with the largest presence in Europe.

Read more
Market cap
71.91M EUR
Turnover
12.99K EUR
P/E (adj.) (27e)
EV/EBIT (adj.) (27e)
P/B (27e)
EV/S (27e)
Dividend yield-% (27e)
Coverage
Recommendation
Accumulate
Target price
Updated
08.10.2026
Disclaimer
Revenue and EBIT-%
EPS and dividend
Financial calendar
Risk
Business risk
Valuation risk
Low
High
All
Research
Webcasts
Press releases
ShowingAll content types

Forum discussions
News from the research side: research.nightingalehealth.com Nightingale’s CoreMetabolomics expands: broader metabolic coverage with 20...
10/20/2026, 6:48 AM
by Pertti
19
Out of interest, I looked closer into Alamar and its business model. Quite an interesting clip on YouTube. Investor-oriented speculation… Only a fifth of Alamar’s revenue actually comes from sample analyses. If/when they land a large order, they might run it through one of their ...
10/5/2026, 10:50 AM
by Cle
18
Antti and Antti Co. have published a new company report on Nightingale. Nightingale Health recently announced that it has signed a service agreement with The Michael J. Fox Foundation valued at approximately EUR 5.8 million. Based on the agreement, we are raising our forecasts, particularl...
10/8/2026, 5:34 AM
by Sijoittaja-alokas
15
Inderes Nightingale Healthin sairastumisriskien tunnistus osaksi The Private GP... Nightingale Health Oyj | Lehdistötiedote | 22.10.2026 klo 09:30:00 EESTNightingale Health (Nasdaq Helsinki: HEALTH; OTCQX: NHLTY, NGHLF) ja yksityinen lääkärikeskus The Private GP Group, jolla...
10/22/2026, 6:32 AM
by Pertti
12
Here are Siltanen’s comments on this as well, regarding the North Karelia wellbeing services county incorporating disease risk identification into health checkups for the unemployed in a pilot starting this October. We consider the news to be a positive step, as public primary healthcare...
10/6/2026, 4:43 AM
by Sijoittaja-alokas
10
Using Google’s NotebookLM and some semi-manual adjustments, I created a PDF presentation that aims to illustrate the results of this new Kaiser and Weill Cornell study in plain Finnish with visuals. drive.google.com NMR_Metabolomics_for_Disease_Prediction_(4).pdf Google Drive file...
10/9/2026, 10:14 AM
by The Ugly Buckling
8
Only clinical applications make Nightingale a valuable player – research helps justify it, but doesn’t in itself generate shareholder value. Both Terveystalo and the North Karelia wellbeing services county are clinical applications, but the real money is abroad. Like in the solutions...
10/9/2026, 7:31 AM
by omegaalpha
6
Read more on our forum
Antti Luiro
Antti Siltanen
Antti Siltanen, Antti Luiro
Show more
Latest research

Latest analysis report

Released: 08.10.2026

Latest extensive report

Released: 13.06.2025

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
5.11.
2026

General meeting '26

9.3.
2027

Interim report Q2'27

Analyst Comment23.10.2026 klo 08.56 by
Antti Siltanen

Nightingale's tests added to health assessments offered by British The Private GP Group

The new contract integrates blood analyses as part of health assessments.

Nightingale Health
Press release22.10.2026 klo 09.30

Nightingale Health's disease risk detection becomes part of annual health assessments at The Private GP Group in the United Kingdom

Nightingale Health
Nightingale: Growth boost from proteomics
Research08.10.2026 klo 10.01 by
Antti Siltanen, Antti Luiro

Nightingale: Growth boost from proteomics

The protein analysis project will generate significant growth for the current fiscal year.

Nightingale Health

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Nightingale's tests integrated into Siun sote's health checks
Analyst Comment06.10.2026 klo 09.11 by
Antti Siltanen

Nightingale's tests integrated into Siun sote's health checks

North Karelia is adopting risk tests as part of statutory health checks.

Nightingale Health
Press release05.10.2026 klo 10.10

Nightingale Health's disease risk detection becomes part of health checks for the unemployed in the Wellbeing Services County of North Karelia in Finland

Nightingale Health
Regulatory press release01.10.2026 klo 17.15

Notice to the Annual General Meeting of Nightingale Health Plc

Nightingale Health
Nightingale secures a major 5.8 MEUR project with the Michael J. Fox Foundation
Analyst Comment02.10.2026 klo 10.30 by
Antti Luiro

Nightingale secures a major 5.8 MEUR project with the Michael J. Fox Foundation

To the best of our knowledge, this is the company’s most valuable commercial contract to date and demonstrates once again the company’s ability to carry out large-scale research projects.

Nightingale Health
Regulatory press release01.10.2026 klo 08.30

Nightingale Health’s Annual Report for financial year 2025–2026 has been published

Nightingale Health
Regulatory press release30.09.2026 klo 20.09

Inside information: Nightingale Health signs USD 6.5 million proteomics agreement with the Michael J. Fox Foundation for neurodegenerative disease research

Nightingale Health
Press release29.09.2026 klo 09.00

Nightingale Health's disease risk detection becomes available in Latvia through Professor Skride's Heart Clinic

Nightingale Health
Regulatory press release28.09.2026 klo 12.56

Conversion of Nightingale Health Plc’s Series A shares to Series B shares

Nightingale Health
Agreement between Nightingale and Archipelago Health
Analyst Comment24.09.2026 klo 08.31 by
Antti Siltanen

Agreement between Nightingale and Archipelago Health

The service agreement opens a new distribution channel to the Caribbean and the British Crown Dependencies.

Nightingale Health
Press release23.09.2026 klo 09.52

Nightingale Health and Archipelago Health enter into agreement to bring the Nightingale Health Check to the Crown Dependencies, Bermuda and the Caribbean

Nightingale Health
Nightingale's tests to become part of Coronaria's weight management service
Analyst Comment22.09.2026 klo 09.15 by
Antti Siltanen

Nightingale's tests to become part of Coronaria's weight management service

Numerous small contracts support our growth forecasts.

Nightingale Health
Press release22.09.2026 klo 07.20

Nightingale Health's Remote Health Check becomes part of Coronaria's new weight management service in Finland

Nightingale Health
Nightingale H2'26: The mission is clear – deals, deals, deals!
Research17.09.2026 klo 10.52 by
Antti Siltanen, Antti Luiro

Nightingale H2'26: The mission is clear – deals, deals, deals!

The company is investing fully in sales to achieve its growth targets.

Nightingale Health
Nightingale Health H2'26: Projects are progressing24:54
Video16.09.2026 klo 16.57 by
Antti Siltanen

Nightingale Health H2'26: Projects are progressing

During the second half of the financial year, Nightingale Health's revenue grew to 3.09 MEUR.

Nightingale Health
Nightingale Health 2025–2026 Results Webcast
Webcast16.09.2026 klo 14.00

Nightingale Health 2025–2026 Results Webcast

Nightingale Health
Regulatory press release16.09.2026 klo 09.00

Nightingale Health Plc Financial Statements Release 1 July 2025 – 30 June 2026

Nightingale Health
Nightingale to start Eloisa pilot in public healthcare
Analyst Comment15.09.2026 klo 08.19 by
Antti Siltanen

Nightingale to start Eloisa pilot in public healthcare

The Eloisa project opens the door towards public healthcare.

Nightingale Health